- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 23, 2020
Product Development
Thirteen years from founding, Epizyme scores first FDA approval
Epizyme’s foundational epigenetics hypothesis pays off with approval of first-in-class drug for epithelioid sarcoma
BioCentury | Apr 14, 2016
Distillery Therapeutics
Therapeutics: Histone methyltransferase DOT1L (DOT1L); bromodomain containing 4 (BRD4)
BioCentury | Jan 15, 2015
Product R&D
Epizyme's mantle piece
Epizyme's next first-in-class histone methyltransferase cancer compound
Items per page:
1 - 10 of 36